A Novel Chemotherapy Targeting System based on Nanoparticles
A research team at the University of Strathclyde has successfully developed a method for attaching anticancer drug molecules and targeting groups to metal nanoparticles to provide significant therapeutic benefits. In Vitro studies using Cisplatin nanoparticles demonstrated significantly better cytotoxicity than with Cisplatin alone and an unusual ability to penetrate the cell nucleus – offering enormous improvement over existing anticancer treatments. Key Benefits
- Improved targeting of cancer cells, leading to reduced chemotherapy side effects
- Better targeting provides higher cancer cell kill rates
- This, in turn, decreases the tendency to develop resistance
- In cells which have already acquired resistance, enhanced targeting helps to overcome this
Applications
- This approach allows a much larger number of drug molecules to attach to each nanoparticle, resulting in significantly higher concentrations of chemotherapy molecules–and potentially the treatment of diseases other than Cancer. This would allow for a faster treatment cycle and use by patients with more advanced disease.
- Nanoparticle-based delivery also enables administration of these drugs to occur via a wide range of approaches-from injection to inhalation. In addition to use with human patients, the technology lends itself to veterinary applications.
IP Status
The technology is protected by a patent application filed by the University of Strathclyde as
GB909435.0. Contact is welcomed from organisations interested in developing, licensing
or exploiting this technology.
If you would like further information about
this opportunity please fill out the form below. Your enquiry will
be passed on to the relevant University who will respond to you directly.
